Climate Real Impact Solutions II Acquisition Corp. Class A CLIM 深 滬
等待開盤 10-08 09:30:00 美东时间
10.03
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 10.03
- 總市值 3.03亿
- 52周最高 10.04
- 市盈率 靜 85.29
- 換手率 0.00%
- 52周最低 9.71
- 委 比 0.00%
- 總股本 3018.75万
- 歷史最高 10.20
- 量 比 0
- 振 幅 0.00%
- 歷史最低 9.55
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Canada Life launches suite of Index ETF segregated funds
WINNIPEG, MB, Oct. 7, 2025 /CNW/ - The Canada Life Assurance Company ("Canada Life"), announced the launch of five new Index ETF segregated funds (collectively, the "Index ETF Funds"): Canad...
10-07 20:00
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
Climb Bio announced positive preclinical CLYM116 data showing reduced IgA and a longer half-life versus first-generation anti-APRIL antibodies. CLYM116's Phase 1 trial starts in Q4 2025, with early results in mid-2026. CLYM116's novel mechanism targets IgA nephropathy, representing a $10-20B market opportunity.
09-29 11:00
10连板妖股提示交易风险：收购资金尚未到位 | 盘后公告精选
“卖身”芯片厂的资本新宠发布异动公告，电子元器件分销龙头遭股东拟减持不超3%股份，创新药概念股拟定增募资不超过12.53亿元......
09-09 21:16
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
Climb Bio, Inc., a clinical-stage biotechnology company targeting immune-mediated diseases, announced that its executives will participate in several upcoming investor conferences in September 2025. The events include fireside chats and one-on-one meetings in New York and a virtual presentation. Investors can access live webcasts and replays via its website.
08-25 18:41
香港交易所旗下CORE CLIMATE与建明资源签署碳信用协议 支持企业低碳转型
9月13日，香港交易所宣布，建明资源集团有限公司已从香港交易所旗下的国际碳市场Core Climate购买超过20万吨的自愿碳信用，该公司为专门从事自然资源砂勘...
2023-09-13 16:18
Investing in Decarbonization Across Dow
NORTHAMPTON, MA / ACCESSWIRE / August 30, 2023 / DOW Originally published in Do...
2023-08-31 03:35
Seagen(SGEN.US)双重HER2靶向疗法组合达到3期临床终点
据Seagen(SGEN.US)公告显示，人表皮生长因子受体2(HER2)靶向疗法Tukysa(tucatinib)与HER2靶向抗体偶联药物Kadcyla联用，在3期临床试验HER2CLIMB-02中达到了无进展生存期的主要终点。
2023-08-17 07:13
Seagen Phase 3 Trial Of TUKYSA In Combination With Antibody-Drug Conjugate Ado-Trastuzumab Emtansine Meets Primary Endpoint Of Progression-Free Survival In Patients With Previously Treated HER2-Positive Metastatic Breast Cancer
Seagen Inc. (NASDAQ:SGEN) today announced that the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA® (tucatinib) in combination with the antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla®) met its
2023-08-16 20:02
PotlatchDeltic 2022 ESG Report: UN Sustainable Development Goals
NORTHAMPTON, MA / ACCESSWIRE / August 1, 2023 / PotlatchDeltic UN SUSTAINABLE D...
2023-08-01 09:15
基因编辑疗法获得FDA关键称号 CRISPR Therapeutics(CRSP.US)和福泰制药(VRTX.US)涨跌不一
CRISPR Therapeutics和福泰制药周五盘前交易走高。
2023-06-09 21:37
